↓ Skip to main content

An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial

Overview of attention for article published in Clinical and Translational Allergy, February 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)

Mentioned by

twitter
4 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
Published in
Clinical and Translational Allergy, February 2016
DOI 10.1186/s13601-016-0093-z
Pubmed ID
Authors

A. M. Chaker, B. Al-Kadah, U. Luther, U. Neumann, M. Wagenmann

Abstract

The number of injections in the dose escalation of subcutaneous immunotherapy (SCIT) is small for some currently used hypoallergenic allergoids, but can still be inconvenient to patients and can impair compliance. The aim of this trial was to compare safety and tolerability of an accelerated to the conventional dose escalation scheme of a grass pollen allergoid. In an open label phase II trial, 122 patients were 1:1 randomized for SCIT using a grass pollen allergoid with an accelerated dose escalation comprising only 4 weekly injections (Group I) or a conventional dose escalation including 7 weekly injections (Group II). Safety determination included the occurrence of local and systemic adverse events. Tolerability was assessed by patients and physicians. Treatment-related adverse events were observed in 22 (36.1 %) patients in Group I and 15 (24.6 %) in Group II. Local reactions were reported by 18 patients in Group I and 11 in Group II. Five Grade 1 systemic reactions (WAO classification) were observed in Group I and 2 in Group II. Grade 2 reactions occurred 3 times in Group I and 2 times in Group II. Tolerability was rated as "good" or "very good" by 53 (86.9 %) patients in Group I and 59 (100 %) in Group II by investigators. Forty-eight patients in Group I (80.0 %) and 54 in Group II (91.5 %) rated tolerability as "good" or "very good". The dose escalation of a grass pollen allergoid can be accelerated with safety and tolerability profiles comparable to the conventional dose escalation.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 31%
Student > Master 2 15%
Lecturer 1 8%
Lecturer > Senior Lecturer 1 8%
Other 1 8%
Other 1 8%
Unknown 3 23%
Readers by discipline Count As %
Medicine and Dentistry 4 31%
Immunology and Microbiology 2 15%
Agricultural and Biological Sciences 2 15%
Social Sciences 1 8%
Physics and Astronomy 1 8%
Other 0 0%
Unknown 3 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 July 2017.
All research outputs
#8,254,079
of 15,295,300 outputs
Outputs from Clinical and Translational Allergy
#312
of 466 outputs
Outputs of similar age
#132,657
of 343,222 outputs
Outputs of similar age from Clinical and Translational Allergy
#1
of 1 outputs
Altmetric has tracked 15,295,300 research outputs across all sources so far. This one is in the 45th percentile – i.e., 45% of other outputs scored the same or lower than it.
So far Altmetric has tracked 466 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,222 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them